Stocktoria

EXELIXIS, INC. EXEL

Nasdaq · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2000-04-11 · LEI

EXELIXIS, INC. financials (annual)

Revenue
$191.5M $452.5M $853.8M $967.8M $987.5M $1.43B $1.61B $1.83B $2.17B $2.32B 2016201720182020202120212022202320252026
Net income
-$70.2M $154.2M $690.1M $321.0M $111.8M $231.1M $182.3M $207.8M $521.3M $782.6M 2016201720182020202120212022202320252026
Free cash flow
$204.6M $144.5M $382.4M $514.1M $178.6M $346.6M $334.9M $292.9M $671.5M $875.8M 2016201720182020202120212022202320252026

Bars are annual figures from 2016 to 2026; red bars are negative (a loss or cash outflow).

MetricFY2026FY2025FY2023FY2022FY2021FY2021FY2020FY2018FY2017FY2016
Revenue$2.3B$2.2B$1.8B$1.6B$1.4B$987.5M$967.8M$853.8M$452.5M$191.5M
R&D expense$825.0M$910.4M$1.0B$891.8M$693.7M$547.9M$337.0M$182.3M$112.2M$96.0M
SG&A expense$518.7M$492.1M$542.7M$459.9M$401.7M$293.4M$228.2M$206.4M$159.3M$116.1M
Operating income$872.2M$604.6M$170.9M$201.5M$286.7M$110.1M$369.5M$438.9M$165.9M-$28.1M
Interest expense$0$0$8.7M$33.1M
Income tax$158.6M$160.4M$49.8M$52.1M$63.1M$19.1M$77.1M-$238.0M$4.3M$0
Net income$782.6M$521.3M$207.8M$182.3M$231.1M$111.8M$321.0M$690.1M$154.2M-$70.2M
EPS (diluted)$2.78$1.76$0.65$0.56$0.72$0.35$1.02$2.21$0.49
Operating cash flow$884.3M$700.0M$333.3M$362.6M$400.8M$209.0M$527.0M$415.7M$165.6M$206.3M
Free cash flow$875.8M$671.5M$292.9M$334.9M$346.6M$178.6M$514.1M$382.4M$144.5M$204.6M
Cash & equivalents$482.5M$217.4M$263.0M$501.2M$647.2M$319.2M$266.5M$314.8M$183.2M$151.7M
Inventory$21.7M$22.4M$17.3M$33.3M$27.5M$21.0M$12.9M$9.8M$6.7M$3.3M
Total assets$2.8B$2.9B$2.9B$3.1B$2.6B$2.1B$1.9B$1.4B$655.3M$595.7M
Total liabilities$683.1M$703.5M$678.4M$583.1M$405.6M$258.2M$199.7M$134.8M$370.3M$506.4M
Shareholders' equity$2.2B$2.2B$2.3B$2.5B$2.2B$1.9B$1.7B$1.3B$285.0M$89.3M

Growth · year-over-year · Revenue CAGR 31.9%

MetricFY2026FY2025FY2023FY2022FY2021FY2021FY2020FY2018FY2017FY2016
Revenue growth+7.0%+18.5%+13.6%+12.3%+45.3%+2.0%+13.3%+88.7%+136.3%+0.0%
Net income growth+50.1%+150.9%+14.0%-21.1%+106.7%-65.2%-53.5%+347.4%
EPS growth+58.0%+170.8%+16.1%-22.2%+105.7%-65.7%-53.8%+351.0%
Free cash flow growth+30.4%+129.3%-12.6%-3.4%+94.0%-65.3%+34.4%+164.7%-29.4%-2.0%

Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.

Computed from company filings · US · as of 2026-01-02. Facts plus Stocktoria's own computed scores — not investment advice.